Analyst Insights

Intel Corporation Upgraded to Buy From Neutral At Roth Capital

Analyst Krishna Shankar of Roth Capital upgraded Intel Corporation (INTC) from Neutral to Buy, and boosted his price target on INTC from $28.00 to $35.

Roth Capital Maintains Buy Rating On Uranium Resources

Roth Capital reiterated coverage yesterday on Uranium Resources Inc. (URRE) with a Buy rating and $4.

UPDATE: Roth Capital Resumes Coverage On Conatus Pharmaceuticals

In a report published today, Roth Capital analyst Ed Arce resumed coverage on Conatus Pharmaceuticals Inc. (CNAT) with a Buy rating and $19.

We See An Attractive Risk/Reward In MPAA Shares, Says Roth Capital Analyst

In a research note issued this morning, Roth Capital maintained coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA) and a price target of $30.

Capstone Turbine Represents An Attractive Entry Point For LT Holders, Says Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Capstone Turbine Corp. (CPST) and a price target of $1.

CTI BioPharma Reiterated With A Buy At H.C. Wainwright

In a research note issued this morning, H.C.

We Continue To Remain Supportive Of Vertex Shares, Says Janney Analyst

In a research note released this morning, Janney Montgomery Scott reiterated coverage on Vertex Pharmaceuticals (VRTX) with an Outperform rating and $90 fair value estimate. A data …

William Blair Reiterates Outperform On Encore Capital

In a research note released today, William Blair reiterated coverage on Encore Capital Group, Inc (ECPG) with an Outperform rating. Blair analyst Robert Napoli has increased confidence in Encore’s long-term growth …

Wedbush Reiterates An Outperform Rating On Smith & Wesson; Expects Market Share Gains

In a research note issued today, Wedbush reiterated coverage with a “Buy” rating on Smith & Wesson (SWHC), and a price target of $20.00 a share.

We Like Ariad’s Story But See Limited Newsflow, Says UBS’ Andrew Peters

Ariad Pharmaceuticals (ARIA) had its price target reduced by UBS from $7.50 to $7.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts